Article Sidebar
Views pdf: 65
SUSCEPTIBILITY OF ENTEROBACTERALES TO CEFTAZIDIME-AVIBACTAM AT UNIVERSITY MEDICAL CENTER HO CHI MINH CITY
Main Article Content
Abstract
Background: Ceftazidime-avibactam is a new generation β-lactam/β-lactamase inhibitor combination antibiotic recommended for the treatment of serious infections caused by multidrug-resistant bacteria. In Vietnam, this antibiotic has only recently been introduced, so there are few reports on its susceptibility. Objectives: To determine the susceptibility of Enterobacterales to ceftazidime-avibactam at University Medical Center Ho Chi Minh City. Methods: Enterobacterales isolated from clinical specimens at University Medical Center Ho Chi Minh City from February 2023 to January 2024 were identified using the BD Phoenix M50 (Becton Dickinson, USA) and Vitek 2 Compact (Bio-Mérieux, France) automated identification systems. The MICs of antibiotics were determined using the NMIC500 CPO automated kit on the BD Phoenix M50 system (Becton Dickinson, USA). Susceptibility to antibiotics was interpreted according to CLSI 2025 criteria. Results: Among 1961 isolates of Enterobacterales from patients with respiratory infections, bacteremia, urinary tract infections, skin and soft tissue infections, abdominal infections, and other infections, E. coli and K. pneumoniae were the two leading pathogens with rates of 39% and 37%, respectively. The susceptibility rate of Enterobacterales to ceftazidime-avibactam was 85.2%, and the susceptibility rate of carbapenem-resistant Enterobacterales (CRE) was 45.3%. The susceptibility rate of ceftazidime-avibactam for E. coli was 96.3%, and that for carbapenem-resistant E. coli was 68.3%. The susceptibility rate of ceftazidime-avibactam for K. pneumoniae was 72.0%, and that for carbapenem-resistant K. pneumoniae was 41.4%. The susceptibility rate of ceftazidime-avibactam for S. marcescens was 58.2%, and that for carbapenem-resistant S. marcescens was 31.7%. Conclusion: Ceftazidime-avibactam remains effective against Enterobacterales. However, the lower susceptibility rates observed in carbapenem-resistant Enterobacterales highlight the need for continued close surveillance of resistance patterns and thorough use to preserve this antibiotic for the treatment of multidrug-resistant Gram-negative bacteria
Article Details
Keywords
Enterobacterales, antimicrobial resistance, ceftazidime-avibactam.
References
2. Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/ Healthcare Infection Society/ British Infection Association Joint Working Party. The Journal of antimicrobial chemotherapy. Mar 1 2018;73(suppl_3):iii2-iii78. doi:10.1093/jac/ dky027
3. Abodakpi H, Chang KT, Zhou J, Byerly C, Tam VH. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Sep 2019;25(9):1154.e9-1154.e14. doi:10.1016/j.cmi.2019.01.003
4. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Apr 2022;28(4):521-547. doi:10.1016/ j.cmi.2021.11.025
5. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Apr 19, 2022.
6. FDA. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2019/206494s005,s006lbl.pdf, truy cập ngày 1/6/2025
7. Quyết định số 226/QĐ-QLD Về việc ban hành danh mục 112 thuốc nước ngoài được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 105 bổ sung. 2021.
8. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. Journal of global antimicrobial resistance. Sep 2020;22:18-27. doi:10.1016/ j.jgar.2019.12.009
9. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrobial agents and chemotherapy. Jul 2018;62(7): e02569-17. doi:10.1128/aac.02569-17
10. Nguyễn Ngọc Châu VNT, Trần Thanh Linh, Lê Phạm Mỹ Dạ, Trương Thiên Phú. Khảo sát mức độ nhạy cảm kháng sinh ceftazidime/ avibactam của Klebsiella pneumoniae ở bệnh nhân Khoa Hồi sức cấp cứu Bệnh viện Chợ Rẫy. Tạp chí Y học Việt Nam. 2024;534(1B):252-256.